Pegaspargase: a review of clinical studies.

[1]  K. Schmiegelow,et al.  Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration , 2001, Cancer Chemotherapy and Pharmacology.

[2]  G. Henze,et al.  Drug monitoring of low‐dose PEG‐asparaginase (Oncaspartm) in children with relapsed acute lymphoblastic leukaemia , 2001, British journal of haematology.

[3]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[4]  B. Pollock,et al.  Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a pediatric oncology group study , 2000 .

[5]  R. Junker,et al.  Prothrombotic Risk Factors in Children with Acute Lymphoblastic Leukemia Treated with Delayed E. coli Asparaginase (COALL-92 and 97 Protocols) , 2000, Thrombosis and Haemostasis.

[6]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[7]  M. Relling,et al.  Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Vora,et al.  Benefit of intensified treatment for all children with acute lymphoblastic leukaemia: results from MRC UKALL XI and MRC ALL97 randomised trials , 2000, Leukemia.

[9]  R. Knöfler,et al.  Clinical importance of prothrombotic risk factors in pediatric patients with malignancy – impact of central venous lines , 1999, European Journal of Pediatrics.

[10]  K. Welte,et al.  Clinical relevance of genetic risk factors for thrombosis in paediatric oncology patients with central venous catheters , 1999, European Journal of Pediatrics.

[11]  H. Kantarjian,et al.  Combination therapy with methotrexate, vincristine, polyethylene‐glycol conjugated‐asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia , 1999, Cancer.

[12]  M. Relling,et al.  Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  R. Junker,et al.  Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. , 1999, Blood.

[14]  M. Amylon,et al.  Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.

[15]  C. Schiffer,et al.  Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia , 1998, Leukemia.

[16]  J. Kurtzberg,et al.  Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia , 1998, Bone Marrow Transplantation.

[17]  A. Tulpule,et al.  PRELIMINARY RESULTS OF PEG-L-ASPARAGINASE (ONCASPAR) IN THE TREATMENT OF RELAPSED/ REFRACTORY AIDS-RELATED LYMPHOMAS. , 1998 .

[18]  H. Hori,et al.  Rapid desensitization for L-asparaginase hypersensitivity. , 1998, The Journal of allergy and clinical immunology.

[19]  T. Ueno,et al.  Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase , 1997, Leukemia.

[20]  S. Schuster,et al.  Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. , 1997, American Journal of Physiology.

[21]  M. Zucchetti,et al.  L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  W. Velasquez,et al.  Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. , 1995, Formulary.

[23]  P. Voûte,et al.  An open‐label, multicenter study of polyethylene glycol‐L‐asparaginase for the treatment of acute lymphoblastic leukemia , 1995, Cancer.

[24]  R. Ragusa,et al.  Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Rutella,et al.  Acute parotitis during induction therapy includingl-asparaginase in acute lymphoblastic leukemia , 1994, Annals of Hematology.

[26]  A. Giles,et al.  Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L'Asparaginase-induced antithrombin III deficiency. , 1994, Blood.

[27]  L. Odom,et al.  Thrombosis in children receiving L-asparaginase. Determining patients at risk. , 1993, The American journal of pediatric hematology/oncology.

[28]  D. Coppola,et al.  Comparative pharmacokinetic studies of three asparaginase preparations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Adachi,et al.  Pre‐treatment of a human T‐lymphoblastoid cell line with L‐asparaginase reduces etoposide‐induced DNA strand breakage and cytotoxicity , 1992, International journal of cancer.

[30]  M. Conese,et al.  Unbalanced Coagulation-Fibrinolysis Potential during L-Asparaginase Therapy in Children with Acute Lymphoblastic Leukaemia , 1990, Thrombosis and Haemostasis.

[31]  C. Spurr,et al.  A phase II trial of peg-L-asparaginase in the treatment of non-hodgkins lymphoma , 1990, Investigational New Drugs.

[32]  H. Mikawa,et al.  Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. , 1989, Leukemia.

[33]  E. Perlin,et al.  Severe hepatotoxicity from Escherichia coli L-asparaginase. , 1987, Journal of the National Medical Association.

[34]  M. Rybak,et al.  Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  R. Gelber,et al.  Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. , 1986, The New England journal of medicine.

[36]  M. Keating,et al.  Clinical pharmacology of polyethylene glycol-L-asparaginase. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[37]  R. Riccardi,et al.  L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. , 1981, Cancer research.

[38]  J. Lobel,et al.  Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood , 1979, Cancer.

[39]  Y. Ashihara,et al.  Modification of E. coli L-asparaginase with polyethylene glycol: disappearance of binding ability to anti-asparaginase serum. , 1978, Biochemical and biophysical research communications.

[40]  D. Hammond,et al.  L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia. , 1977, Cancer research.

[41]  J. Palmblad,et al.  Hypersensitive reactions and antibody formation during L‐asparaginase treatment of children and adults with acute leukemia , 1976, Cancer.

[42]  J. Holland,et al.  Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli , 1972, Cancer.

[43]  J. Howard,et al.  L-asparaginase from Erwinia carotovora. Substrate specificity and enzymatic properties. , 1972, Journal of Biological Chemistry.

[44]  R. Jackson,et al.  Escherichia coli L-asparaginase. Catalytic activity and subunit nature. , 1970, Biochemistry.

[45]  J. Holland,et al.  Biochemical and pharmacological studies with asparaginase in man. , 1970, Cancer research.

[46]  E. Hersh,et al.  The inhibition of lymphocyte blastogenesis by L-asparaginase. , 1970, Blood.

[47]  P. Carbone,et al.  L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. , 1969, The New England journal of medicine.

[48]  C. Haskell,et al.  l-asparaginase resistance in human leukemia--asparagine synthetase. , 1969, Biochemical pharmacology.

[49]  H. P. Hobik.  Immunosuppressive Wirkung vonl-Asparaginase in der Graft-versus-Host-Reaktion , 1969, Naturwissenschaften.

[50]  M. Prager,et al.  Asparagine synthetase in asparaginase resistant and susceptible mouse lymphomas. , 1968, Biochemical and biophysical research communications.

[51]  J. H. Kim,et al.  Inhibition of leukemias in man by L-asparaginase. , 1967, Cancer research.

[52]  J. H. Schwartz,et al.  Differences in the production of L-asparagine in asparaginase-sensitive and resistant lymphoma cells. , 1967, Biochimica et biophysica acta.

[53]  L. Mashburn,et al.  TUMOR INHIBITORY EFFECT OF L-ASPARAGINASE FROM ESCHERICHIA COLI. , 1964, Archives of biochemistry and biophysics.

[54]  J. Broome.  Evidence that the L-Asparaginase Activity of Guinea Pig Serum is responsible for its Antilymphoma Effects , 1961, Nature.

[55]  J. G. Kidd.  REGRESSION OF TRANSPLANTED LYMPHOMAS INDUCED IN VIVO BY MEANS OF NORMAL GUINEA PIG SERUM , 1953, The Journal of experimental medicine.

[56]  F. Balis,et al.  Pharmacokinetics of PEG-l-asparaginase and plasma and cerebrospinal fluidl-asparagine concentrations in the rhesus monkey , 2004, Cancer Chemotherapy and Pharmacology.

[57]  Charles W. Taylor,et al.  A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors , 2001, Cancer Chemotherapy and Pharmacology.

[58]  H. Jürgens,et al.  Enhanced thrombin generation, P-von willebrand factor, P-fibrin D-dimer and P-plasminogen activator inhibitor 1: Predictive for venous thrombosis in asparaginase-treated children , 1994 .

[59]  清水 恒広.  Pretreatment of a human T-lymphoblastoid cell line with L-asparaginase reduces etoposide-induced DNA strand breakage and cytotoxicity , 1992 .

[60]  R. Miniero,et al.  L-asparaginase-induced coagulopathy in children with acute lymphoblastic leukaemia. , 1987, Drugs under experimental and clinical research.

[61]  N. Cheung,et al.  Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. , 1986, The American journal of pediatric hematology/oncology.

[62]  F. Davis,et al.  Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. , 1981, Anticancer research.

[63]  G. Matsuda,et al.  The primary structure of L-asparaginase from Escherichia coli. , 1980, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[64]  M. Weil,et al.  Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. , 1977, Medical and pediatric oncology.

[65]  G. Burgio,et al.  With reference to blastogenesis inhibition by L-asparaginase. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[66]  H. Oettgen,et al.  Experimental and Clinical Effects of L-Asparaginase , 1970, Recent Results in Cancer Research.

[67]  H. Schulten,et al.  Influence of L-asparaginase preparations of E. coli and agouti serum on the homograft reactivity in the mouse. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[68]  U. Fink,et al.  Clinical studies with L-asparaginase in dermatomyositis. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[69]  D. Karnofsky,et al.  Clinical experience with L-asparaginase. , 1970, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[70]  A. Clementi.  La Désamidation Enzymatique De L'asparagine Chez Les Différentes Espéces Animales Et La Signification Physio Logique De Sa Presence Dans L'organisme , 1922 .